Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.

Though lung cancer looks promising a partner is now needed.

The company’s AN9025 will shortly enter phase 1.

With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.

But the group still hopes to get IGV-001 approved based on overall survival data.

A more comprehensive dataset on JANX007 sends the group’s stock down.

The agency approved eight oncology products over the month. 

The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.

Car-T therapies and ADCs feature among recent first-in-human study entrants.

The pivotal Harmoni-GI3 study has started enrolling patients.